IDiyas

For the Inventor, By the Inventor

Hoboken, NJ, United States of America

Brandon Mitsuo Taoka

USPTO Granted Patents = 15 


Average Co-Inventor Count = 8.6

ph-index = 4

Forward Citations = 68(Granted Patents)


Location History:

  • Allston, MA (US) (2013)
  • Brookline, MA (US) (2013)
  • Hoboken, NJ (US) (2014 - 2019)
  • San Francisco, CA (US) (2020 - 2023)

Company Filing History:

goldMedal15 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
silverMedal4 out of 40 
 
Merck Canada Inc.
 patents
where one patent can have more than one assignee

Years Active: 2013-2023

Loading Chart...
Loading Chart...
15 patents (USPTO):
1. 11702430 - Aza-benzothiophene compounds as STING agonists (2023-07-18),
2. 11008338 - C5-C6-oxacyclic fused iminothiazine dioxide compounds bearing an ether linker as BACE inhibitors, compositions, and their use (2021-05-18),
3. 10689401 - C5-C6-oxacyclic fused iminothiazine dioxide compounds bearing an ether linker as BACE inhibitors, compositions, and their use (2020-06-23),
4. 10414775 - Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease (2019-09-17),
5. 10414774 - Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease (2019-09-17),
6. 9732088 - C2-carbocyclic iminothiazine dioxides as BACE inhibitors, compositions, and their use (2017-08-15),
7. 9376418 - Substituted pyridine spleen tyrosine kinase (SYK) inhibitors (2016-06-28),
8. 9242984 - Pyrazolyl derivatives as Syk inhibitors (2016-01-26),
9. 9145391 - Bipyridylaminopyridines as Syk inhibitors (2015-09-29),
10. 8946237 - Pyrazolo[1,5-A]pyrimidines as mark inhibitors (2015-02-03),
11. 8796310 - Amino-pyridine-containing spleen tyrosine kinase (SYK) inhibitors (2014-08-05),
12. 8592425 - Imidazo[1,2-a]pyridines and imidazo[1,2-b]pyridazines as mark inhibitors (2013-11-26),
13. 8551984 - Aminopyrimidines as SYK inhibitors (2013-10-08),
14. 8431569 - Inhibitors of janus kinases (2013-04-30),
15. 8367706 - Inhibitors of janus kinases (2013-02-05),

Title: The Innovative Contributions of Brandon Mitsuo Taoka

Introduction

Brandon Mitsuo Taoka is a prominent inventor based in Hoboken, NJ, known for his significant contributions to the field of pharmaceuticals. With a total of 15 patents to his name, Taoka has made remarkable advancements in the development of compounds that have the potential to treat various medical conditions, including cancer.

Latest Patents

Among his latest patents is the invention of Aza-benzothiophene compounds as STING agonists. These compounds, defined by a specific general formula, are designed to induce type I interferon production, acting as STING active agents. The patent also covers the synthesis processes and potential applications of these compounds, particularly in inducing immune responses and treating cell proliferation disorders. Another notable patent involves C5-C6-oxacyclic fused iminothiazine dioxide compounds bearing an ether linker, which serve as BACE inhibitors. This invention provides various embodiments of these compounds and their applications in pharmaceutical compositions.

Career Highlights

Brandon Taoka has worked with esteemed organizations such as Merck Sharp & Dohme Corporation and Merck Canada Inc. His experience in these companies has allowed him to refine his expertise in pharmaceutical research and development, contributing to his innovative work in the field.

Collaborations

Throughout his career, Taoka has collaborated with notable colleagues, including Michael D. Altman and Andrew M. Haidle. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to groundbreaking discoveries.

Conclusion

Brandon Mitsuo Taoka's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a leading inventor. His work continues to pave the way for advancements in medical treatments and therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…